Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-13

Study Completion Date

2021-11-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (QOL), and symptom assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Evaluating FT-SW in Unilateral Breast Cancer-Related Lymphedema Patients

NCT04073823

Breast Cancer Related Lymphedema

TERMINATED NA

Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

NCT00383500

Lymphedema Breast Cancer

COMPLETED NA

Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer

NCT00880022

Arm Lymphedema Truncal Lymphedema Breast Cancer

COMPLETED NA

Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer

NCT01019512

Breast Cancer Lymphedema

TERMINATED NA

Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device

NCT03252145

Lymphedema, Secondary Lymphedema of Upper Limb

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, on label, prospective, randomized, two-arm feasibility study that plans to enroll 30 female subjects in the United States. In an effort to reduce potential exposure to COVID-19, all study assessments are intended to be performed in a contactless manner (i.e., telephone, video conference, etc). If a subject passes the initial screening requirements via medical history and expresses interest in the study an informed consent form will be provided to them. Once consent has been obtained they will undergo a baseline visit where they will be randomized to one of two treatment groups: PASSIVE FT-CC (text messages reminders will not be sent to subjects) and ACTIVE FT-CC (text messages reminders will be sent if subject does not use the device for 2 consecutive days). Randomization was incorporated into the study to determine if ACTIVE FT-CC affects device use. A total of 2 follow-up visits will be conducted over a 60-day period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACTIVE FT-CC

Text message reminders will be sent if subject does not use the device for 2 consecutive days.

Group Type EXPERIMENTAL

Flexitouch Plus with Cellular Connectivity (FT-CC)

Intervention Type DEVICE

Daily use of FT-CC

PASSIVE FT-CC

Text message reminders will not be sent to subjects.

Group Type EXPERIMENTAL

Flexitouch Plus with Cellular Connectivity (FT-CC)

Intervention Type DEVICE

Daily use of FT-CC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flexitouch Plus with Cellular Connectivity (FT-CC)

Daily use of FT-CC

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female 18 years of age or older
2. Diagnosis of unilateral breast cancer-related lymphedema
3. Willing and able to give informed consent (remotely or in person)
4. Willing and able to comply with the study protocol requirements and all study-related visit requirements, including the ability to participate remotely
5. Willing and able to receive text messages from sponsor

Exclusion Criteria

1. In-home use of PCD within previous 3 months
2. Phase-one CDT within previous 1 month or planned phase-one CDT during study participation Phase-one CDT defined as professionally administered MLD and/or multi-layer short stretch compressive bandaging.
3. Inability to be fit for PCD garments
4. Heart failure (acute pulmonary edema, decompensated acute heart failure)
5. Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
6. Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease) on the arms or trunk
7. Currently receiving treatment for cancer with curative intent.
8. Any circumstance where increased lymphatic or venous return is undesirable
9. Currently pregnant or trying to become pregnant
10. Known inability to receive cell phone connection where FT-CC therapy will be administered

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No